Sunovion Begins Phase 2 Program For Psychotropic Medication

Sunovion Pharmaceuticals, Inc. is entering into its global Phase 2 Program to test the safety, efficacy, and tolerability of an investigational psychotropic agent as treatment for consumers with schizophrenia or Parkinson's disease psychosis. Preliminary findings support the drug's potential to treat both the positive and negative symptoms of schizophrenia, and the hallucinations/delusions caused by Parkinson's Disease.

Sunovion Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to helping those with serious medical conditions through science and medicine. The company is responsible for such medications as Brovana ®, Latuda ®, and Aptiom ®.

This was reported by Business Wire on December . . .